secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aldeyra Therapeutics, Inc. (ALDX)
CIK:        0001341235
Form:       8-K
Filed at:   2026-05-01T23:59:59+00:00
Accession:  0001193125-26-199157
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aldeyra provides reproxalap trial endpoint estimates and FDA stance in corporate overview
--------------------------------------------------------------------------------

- Standardized treatment estimates and confidence intervals disclosed for reproxalap dry eye disease clinical trials primary endpoints.
- Aldeyra summarizes its interpretations of FDA positions on primary endpoints and its own positions in the NDA.
- Presentation is a voluntary Reg FD disclosure; no financial results or guidance included.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1341235/000119312526199157/0001193125-26-199157-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1341235/000119312526199157/aldx-20260501.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-199157

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer